Abstract
This article reviews the prevalence, phenomenology, main clinical correlates, potential mechanisms, and treatment modalities of depression in Parkinson's disease (PD). In cross-sectional samples of PD patients attending a neurology unit the prevalence of depression is about 40%, but prevalences may be lower in epidemiological samples. Both psychological and autonomic symptoms of depression are specific to the depressive syndrome of PD, except for the symptoms of anergia, motor retardation, and early morning awakening. Depression may start before the onset of motor symptoms, and most patients with PD may eventually develop depression at some point during their longitudinal evolution. Follow-up studies suggest that PD patients with major depression have a significantly faster decline in activities of daily living and cognitive functions, and a faster progression along the stages of the illness as compared to non-depressed PD patients. Finally, there are few controlled studies of antidepressants in PD, but tricyclic compounds demonstrated adequate efficacy and tolerability.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
